A Phase 2 trial testing experimental therapy CAL101 in people with IPF is recruiting participants. CAL101 has been granted ...

Columnist Samuel Kirton has nothing but praise for caregivers, who represent the best of what is right in the world.

Guest writer Kylene Henderson's husband had just been diagnosed with PF when they decided to take a family road trip to ...

Blocking caspase-9, an enzyme involved in cell death, may be a potential treatment target for pulmonary fibrosis, a ...

Columnist Samuel Kirton had to put a plan in place after his lung transplant to make sure his drinking water was safe for him to consume.

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to BMS-986278, Bristol Myers Squibb’s investigational therapy for progressive pulmonary fibrosis (PF).

Taking oral dietary supplements of epigallocatechin-3-gallate (EGCG) — an antioxidant in green tea — may stop and reverse the pro-fibrotic (scarring) state of the lungs of people with idiopathic ...

[vc_row][vc_column][vc_column_text] Tipelukast (MN-001) is an oral macromolecular formulation developed originally by Kyorin Pharmaceuticals and now in clinical trials in the United States by ...

BMS-986020 is an anti-fibrotic drug being developed by Bristol-Myers Squibb, and is chemically a lysophosphatidic acid (LPA) receptor antagonist. The drug, an oral formulation, is in clinical trials ...